Entrada Therapeutics, Inc. Stock Analysis & AI Score
Entrada Therapeutics, Inc. (TRDA) has an ST Score of 38.6 (C), driven by its Forecast (B+) and held back by its Growth (D). Analysts rate it Buy with a $14.00 price target (+125.1% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Entrada Therapeutics, Inc. (TRDA) has an ST Score of 38.6 (C), driven by its Forecast (B+) and held back by its Growth (D). Analysts rate it Buy with a $14.00 price target (+125.1% upside).
- Strongest
- ForecastB+
- Weakest
- GrowthD
All factor grades
- ForecastB+
- Financial StrengthB
- MomentumC+
- ProfitabilityC
- ValuationD+
- GrowthD
- Piotroski1/9
Contact
TRDA stock: frequently asked questions
What is TRDA's ST Score?
Entrada Therapeutics, Inc. (TRDA) has an ST Score of 38.6 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is TRDA a buy, hold, or sell?
Analysts rate TRDA a Buy, with a price target of $14.00 (+125.1% vs the current price). Our ST Score grades it C (38.6/100). The ST Score is a data-driven signal, not a recommendation.
What are TRDA's factor grades?
Valuation D+, Profitability C, Financial Strength B, Momentum C+, Growth D, Forecast B+.
What is TRDA's valuation grade?
Entrada Therapeutics, Inc. (TRDA) earns a valuation grade of D+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is TRDA's growth grade?
Entrada Therapeutics, Inc. (TRDA) earns a growth grade of D, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is TRDA's profitability grade?
Entrada Therapeutics, Inc. (TRDA) earns a profitability grade of C, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is TRDA's financial strength grade?
Entrada Therapeutics, Inc. (TRDA) earns a financial strength grade of B, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for TRDA?
The average analyst price target for Entrada Therapeutics, Inc. (TRDA) is $14.00 from 6 analysts, which is +125.1% versus the recent price of $6.22.
What is TRDA's Piotroski score?
Entrada Therapeutics, Inc. (TRDA) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.